Prab: CSV import

2024-12-02T04:03:49Z

CSV import

New page

{{Infobox drug
| name = O-2220
| image = 
| width = 200px
| alt =
| caption =
| legal_status =
| routes_of_administration =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number =
| ATC_prefix =
| ATC_suffix =
| PubChem =
| DrugBank =
| ChemSpiderID =
| UNII =
| KEGG =
| ChEBI =
| ChEMBL =
| synonyms =
}}

'''O-2220''' is a chemical compound that has been studied for its potential effects on the [[endocannabinoid system]]. It is classified as a [[cannabinoid receptor]] agonist, specifically targeting the [[CB1 receptor]].

==Chemical Structure and Properties==
O-2220 is a synthetic compound with a complex chemical structure. The molecular formula and specific stereochemistry are crucial for its activity at the cannabinoid receptors. The compound is typically synthesized in a laboratory setting and is not found naturally.

==Pharmacology==
O-2220 acts as a selective agonist for the CB1 receptor, which is predominantly found in the [[central nervous system]]. Activation of the CB1 receptor by O-2220 can lead to various physiological effects, including modulation of neurotransmitter release, alteration of pain perception, and changes in appetite.

===Mechanism of Action===
The mechanism by which O-2220 exerts its effects involves binding to the CB1 receptor, a G-protein coupled receptor, leading to the inhibition of adenylate cyclase activity. This results in decreased levels of [[cyclic AMP]] and subsequent downstream effects that modulate neuronal excitability and neurotransmitter release.

==Potential Applications==
Research into O-2220 has primarily focused on its potential therapeutic applications. These include:

* '''Pain Management''': Due to its action on the CB1 receptor, O-2220 may have analgesic properties that could be beneficial in managing chronic pain conditions.
* '''Appetite Stimulation''': Similar to other CB1 agonists, O-2220 might be used to stimulate appetite in conditions such as cachexia or anorexia.

==Research and Development==
O-2220 is still under investigation, and much of the research is preclinical. Studies are ongoing to better understand its pharmacokinetics, safety profile, and potential therapeutic uses.

==Safety and Toxicology==
As with many synthetic cannabinoids, the safety profile of O-2220 is not fully established. Potential side effects could include those commonly associated with CB1 receptor activation, such as dizziness, dry mouth, and altered mental status.

==Legal Status==
The legal status of O-2220 varies by jurisdiction. It is important for researchers and clinicians to be aware of the regulatory framework governing the use of synthetic cannabinoids in their region.

==Also see==
* [[Cannabinoid receptor]]
* [[CB1 receptor]]
* [[Endocannabinoid system]]
* [[Synthetic cannabinoids]]

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Pharmacology]]
[[Category:Research chemicals]]

O-2220 - Revision history

Prab: CSV import